Brokers Set Expectations for Humacyte FY2025 Earnings

Humacyte, Inc. (NASDAQ:HUMA) – Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Humacyte in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings per share of ($0.95) for the year. The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share.

Other research analysts also recently issued research reports about the stock. TD Cowen reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. Benchmark lifted their target price on shares of Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, December 23rd. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price (up from $12.00) on shares of Humacyte in a research note on Friday, December 20th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Tuesday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Humacyte currently has a consensus rating of “Buy” and an average target price of $13.71.

Humacyte Stock Performance

NASDAQ HUMA opened at $4.59 on Thursday. The company has a market capitalization of $577.70 million, a price-to-earnings ratio of -3.43 and a beta of 1.32. The company’s 50-day simple moving average is $4.52 and its two-hundred day simple moving average is $5.64. Humacyte has a one year low of $2.80 and a one year high of $9.97.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Friday, November 8th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.08). During the same quarter last year, the firm earned ($0.25) EPS.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently modified their holdings of HUMA. State Street Corp grew its holdings in shares of Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after buying an additional 1,895,529 shares in the last quarter. Millennium Management LLC boosted its position in shares of Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after acquiring an additional 1,334,641 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Humacyte by 693.0% during the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after acquiring an additional 524,600 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Humacyte by 3,301.5% during the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after acquiring an additional 450,031 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new position in Humacyte in the second quarter valued at about $1,550,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Insider Buying and Selling at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the completion of the sale, the chief executive officer now directly owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. The trade was a 13.12 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,500,000 shares of company stock worth $6,606,799. Company insiders own 11.20% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.